Monte Rosa Therapeutics (GLUE)
Nasdaq Market Closed
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company focused on targeted protein degradation, a drug development approach that aims to remove disease-driving proteins rather than simply inhibit them. The company’s shares trade under the symbol GLUE, reflecting its emphasis on molecular glue degraders, a class of small molecules designed to redirect the body’s natural protein disposal machinery toward selected targets.
Molecular glue degraders work by promoting interactions between disease-relevant proteins and cellular degradation systems, such as ubiquitin ligases. This can make it possible to address proteins that have historically been difficult to drug with conventional small-molecule inhibitors or antibodies. Monte Rosa uses its QuEEN discovery platform, which combines computational methods, artificial intelligence, chemical biology, and proprietary experimental tools, to identify target proteins and design degrader candidates.
The company has several programs in clinical development. MRT-6160 is a VAV1-directed molecular glue degrader being studied for immune-mediated diseases. MRT-8102 targets NEK7 and is being developed for inflammatory conditions linked to IL-6 biology and the NLRP3 inflammasome. MRT-2359 is a GSPT1-directed degrader being evaluated in metastatic castration-resistant prostate cancer. Together, these programs show the company’s strategy of applying targeted degradation across immunology, inflammation, and oncology.
Monte Rosa is part of a broader biotech field seeking to turn protein degradation into a new therapeutic modality. Its prospects depend on demonstrating that its degraders can achieve selective activity, manageable safety, and clinically meaningful outcomes in patients. As with many clinical-stage biotechnology companies, GLUE is shaped by trial progress, data readouts, regulatory pathways, cash needs, and the competitive pace of innovation in next-generation small-molecule drug discovery.
Last updated
- Market Cap
- $1,395,599,985
- P/E
- —
- P/FCF
- —
- P/S
- 32.49
- Enterprise Value
- $1,235,740,985
- Sector
- Materials
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 321 HARRISON AVENUE, BOSTON, MA, 02118
Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering
Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases
Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $1,395,599,985
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $1,235,740,985
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.67
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 32.49
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -8.83
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 28.77
- EPS
- -1.54
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -$19,656,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -24.91%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -17.65%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 9.54
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 9.54
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 2.25
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $1,756,139
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 16.52
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 4.21M | 2.78M | 12.77M | 23.19M | 84.93M |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 4.21M | 2.78M | 12.77M | 23.19M | 84.93M |
| Operating income | -50.03M | -49.72M | -32.98M | -15.55M | 44.04M |
| EBITDA | -48.01M | -47.63M | -30.88M | -13.43M | 46.08M |
| Net income | -44.5M | -46.14M | -27.08M | -12.3M | 46.89M |
| Income taxes | 52K | 59K | -3.18M | 1.2M | 822K |
| Other operating expenses | 0 | 0 | 0 | 0 | 0 |
| Total operating expenses | 54.24M | 52.5M | 45.74M | 38.75M | 40.89M |
| Basic EPS | -0.45 | -0.55 | -0.33 | -0.15 | 0.57 |
| Diluted EPS | -0.45 | -0.55 | -0.33 | -0.15 | 0.57 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 736.43M | 448.66M | 459.84M | 359.59M | 393.2M |
| Total liabilities | 214.51M | 215.6M | 214M | 91.51M | 118.04M |
| Total equity | 521.92M | 233.06M | 245.84M | 268.08M | 275.16M |
| Cash & equivalents | 159.86M | 129.88M | 208.34M | 69.43M | 78.53M |
| Current assets | 677.55M | 393.19M | 401.82M | 299.47M | 332.28M |
| Current liabilities | 71.04M | 64.21M | 61.44M | 41.85M | 59.22M |
| Accounts payable | 33.49M | 30.24M | 14.51M | 5.58M | 6.49M |
| Receivables | 4.61M | 11.6M | 4.97M | 2.37M | 1.41M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -37.37M | -43.01M | 100.43M | -34.72M | -45.49M |
| Investing cash flow | -261M | -65.07M | 38.14M | 25.32M | -100.23M |
| Financing cash flow | 328.34M | 29.62M | 348K | 365K | 14K |
| Change in cash | 29.97M | -78.46M | 138.91M | -9.03M | -145.71M |
| Net income | -44.5M | -46.14M | -27.08M | -12.3M | 46.89M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Monte Rosa Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Warmuth Markus | View Filing | |
| edgar index | 144 — Monte Rosa Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Champoux Jennifer | View Filing | |
| form 4 | Form 4 — Champoux Jennifer | View Filing | |
| form 4 | Form 4 — Champoux Jennifer | View Filing | |
| edgar index | SCHEDULE 13G/A — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | SCHEDULE 13D/A — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Townson Sharon | View Filing | |
| form 4 | Form 4 — Townson Sharon | View Filing | |
| form 4 | Form 4 — Townson Sharon | View Filing | |
| form 4 | Form 4 — Townson Sharon | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Behbahani Ali | View Filing | |
| form 4 | Form 4 — Behbahani Ali | View Filing | |
| form 4 | Form 4 — Behbahani Ali | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Monte Rosa Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Janku Filip | View Filing | |
| form 4 | Form 4 — Janku Filip | View Filing | |
| form 4 | Form 4 — Janku Filip | View Filing | |
| edgar index | 144 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Monte Rosa Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Manning Anthony M. | View Filing | |
| form 4 | Form 4 — Manning Anthony M. | View Filing | |
| form 4 | Form 4 — Manning Anthony M. | View Filing | |
| form 4 | Form 4 — Janku Filip | View Filing | |
| form 4 | Form 4 — Janku Filip | View Filing | |
| form 4 | Form 4 — Janku Filip | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Monte Rosa Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Janku Filip | View Filing | |
| form 4 | Form 4 — Janku Filip | View Filing | |
| form 4 | Form 4 — Janku Filip | View Filing | |
| edgar index | 144 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Monte Rosa Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Champoux Jennifer | View Filing | |
| form 4 | Form 4 — Champoux Jennifer | View Filing | |
| form 4 | Form 4 — Champoux Jennifer | View Filing | |
| form 4 | Form 4 — Townson Sharon | View Filing | |
| form 4 | Form 4 — Townson Sharon | View Filing | |
| form 4 | Form 4 — Townson Sharon | View Filing | |
| form 4 | Form 4 — Janku Filip | View Filing | |
| form 4 | Form 4 — Janku Filip | View Filing | |
| form 4 | Form 4 — Janku Filip | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 144 — Monte Rosa Therapeutics, Inc. | View Filing | |
| form 4 | Form 4 — Townson Sharon | View Filing | |
| form 4 | Form 4 — Townson Sharon | View Filing | |
| form 4 | Form 4 — Townson Sharon | View Filing | |
| form 4 | Form 4 — Champoux Jennifer | View Filing | |
| form 4 | Form 4 — Champoux Jennifer | View Filing | |
| form 4 | Form 4 — Champoux Jennifer | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 4 — Monte Rosa Therapeutics, Inc. | View Filing | |
| edgar index | 8-K — Monte Rosa Therapeutics, Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — Hughes Eric A | View Filing | |
| form 4 | Form 4 — Blackwell Kimberly | View Filing | |
| form 4 | Form 4 — Manning Anthony M. | View Filing | |
| form 4 | Form 4 — SCHIFF ANDREW N | View Filing |